Continuous glucose monitoring (CGM) technology provides real-time glucose concentration data to people with diabetes. The data enable timely treatment decisions that can lead to avoidance or mitigation of hypoglycaemia, with potential cost savings. This commentary discusses CGM implementation and funding policies in the UK, and regional disparities that confront many people with diabetes who could benefit from the technology.
Continuous glucose monitoring, commissioning, hypoglycaemia
Nick Oliver has received research support from Dexcom, Inc. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the editorial board for accuracy before publication.
Open Access: This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original.
July 03, 2017
August 22, 2017
Nick Oliver, Section of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Imperial College, Du Cane Road, London, W12 0HS, UK. E: Nick.firstname.lastname@example.org
The publication of this article was supported by Dexcom, Inc. The views and opinions expressed are those of the author and do not necessarily reflect those of Dexcom, Inc.